Aleksey Gerasyuto is a medicinal chemistry leader with deep expertise in computationally driven drug discovery. He champions “Predict-First” approach, integrating modern physics-based and AI/ML methods to accelerate and guide medicinal chemistry campaigns.

At Schrödinger, Aleksey leads the Medicinal Chemistry, CMC and Toxicology teams, and co-leads the strategic oversight and execution of the company's proprietary and collaborative discovery portfolio. Prior to joining Schrödinger, Aleksey held roles of increasing responsibilities at PTC Therapeutics, where he led and contributed to programs in RNA splicing, antibacterial discovery and oncology.

His work has contributed to the discovery of multiple clinical candidates, including: PTC518 for Huntington’s disease (Phase 2), MORF-057 for IBD (Phase 2), SGR-3515 for solid tumors (Phase 1), LOXO-783 for breast cancer and other tumors (Phase 1)
Aleksey earned his Ph.D. from the University of Wisconsin–Madison and his B.S./M.S. from the Higher Chemical College of the Russian Academy of Sciences.